Putting Deals through a Microscope | Traversing Transactions attempts at dissecting a deal by analyzing various aspects and nuances of an M&A Transaction, traversing through a complex mesh of Commercial, Regulatory, and Tax ("CRT") imperatives!
Putting Deals through a Microscope | Traversing Transactions attempts at dissecting a deal by analyzing various aspects and nuances of an M&A Transaction, traversing through a complex mesh of Commercial, Regulatory, and Tax ("CRT") imperatives!
(First published in The Hindu Business Line: https://www.thehindubusinessline.com/markets/pharma-firms-qip-plans-hit-regulatory-wall/article69299050.ece)
My take, as quoted in The Hindu Business Line, on the recent informal guidance issued by SEBI on non-grandfathering of listing legacy upon demerger, if an unlisted transferor company is also involved along with a listed transferor company:
